

Invesco Health Care Fund[®]

Quarterly Performance Commentary

Mutual Fund Retail Share Classes
Data as of Sept. 30, 2020



Investment objective

The fund seeks long-term growth of capital.

Portfolio management

Henry Wu

Fund facts

Nasdaq	A: GGHCX	C: GTHCX
	Investor: GTHIX	Y: GGHYX
Total Net Assets	\$1,484,749,827	
Total Number of Holdings	85	
Annual Turnover (as of 10/31/19)	11%	
Distribution Frequency	Annually	

Top holdings

	% of total net assets
Thermo Fisher Scientific	5.91
UnitedHealth	4.82
Johnson & Johnson	4.11
AstraZeneca	4.09
Novartis ADR	3.93
Medtronic	3.79
Abbott Laboratories	3.03
Eli Lilly	2.62
Vertex Pharmaceuticals	2.60
Sanofi ADR	2.59

Top contributors

	% of total net assets
1. Thermo Fisher Scientific	5.09
2. UnitedHealth	4.79
3. AstraZeneca	4.41
4. BioMarin Pharmaceutical	2.11
5. Immunomedics	0.92

Top detractors

	% of total net assets
1. Biogen	2.37
2. Iovance Biotherapeutics	0.48
3. Lyra Therapeutics	0.11
4. Elanco Animal Health	0.59
5. Stryker	0.49

Not a deposit; Not FDIC insured; Not guaranteed by the bank; May lose value; Not insured by any federal agency

Market overview

+ The global spread of the novel coronavirus continued into the second quarter of 2020. However, during the quarter, many countries achieved some success in controlling the spread and were able to slowly reopen their economies. Economic data indicates that the economies of most countries bottomed at the height of their respective lockdowns. Global equity markets benefited from government policy response to the

crisis, which was swift and encouraging. Many economies received fiscal stimulus and very significant monetary stimulus. The massive monetary policy response created a second quarter environment in which investors embraced risk. Stocks rose globally after a deep rout in the first quarter. Both developed and emerging markets performed well, with developed markets slightly outperforming emerging markets.

Positioning and outlook

+ The fund is currently overweight biotechnology, life science tools and services, health care providers and health care technology. The fund is currently underweight pharmaceuticals and health care equipment and supplies.

+ Looking ahead, we continue to adhere to the

fund's investment process employing domain expertise and primary research focused on our proprietary insights. Given the speed of the decline in global equity markets, we see many mispriced opportunities - created by irrational selling - where our analysis shows risk-reward tilts significantly in the fund's favor.

Performance highlights

+ The fund's Class A shares at net asset value (NAV) outperformed its index in the second quarter. (Please see the investment results table on page 2 for fund and index performance.)

+ Stock selection within biotechnology was the greatest relative contributor during the quarter as portfolio holdings benefited from: estimates for launches of new cystic fibrosis treatments exceeding expectations; announcements of positive clinical trial data in breast cancer; and greater investor appreciation for an upcoming gene therapy product launch in hemophilia, among other drivers. An underweight position and stock selection in pharmaceuticals contributed to relative return. Stock selection in life science tools and services, health care technology and health care providers also added to relative return.

+ Health care equipment and supplies was the only subsector that detracted from relative performance.

Contributors to performance

+ The fund's leading contributor was **Thermo Fisher Scientific**, whose second quarter revenue beat analyst estimates by more than expected, primarily driven by robust global sales of PCR tests and other services and products for combating COVID-19.

+ **UnitedHealth's** integrated strategy and uncanny ability to remain at the leading edge of change has resulted in some of the best returns in the industry in recent years. We believe the firm will be one of the key leaders in bending the health care cost curve in the US.

+ In addition to its COVID-19 vaccine candidate, **AstraZeneca** has a strong oncology portfolio and immunology presence.

Detractors from performance

+ The fund's leading detractor was **Biogen**, in part due to the company losing a Tecfidera (a multiple sclerosis treatment) patent ruling to Mylan (not a fund holding) in June. However, the firm's diversified revenue stream in several other therapies supports future cash flow beyond Tecfidera.

+ We initiated a position in **Iovance Biotherapeutics** during the quarter and while the stock has since declined, we maintain a constructive outlook on the company's promising therapies for melanoma, cervical and other cancers.

+ We initiated a position in **Lyra Therapeutics** during the quarter and though the stock has been down since our purchase, we are optimistic about the company's clinical-stage therapeutics for ear, nose and throat diseases.

Top industries	% of total net assets
Pharmaceuticals	31.49
Health Care Equipment	18.51
Biotechnology	15.84
Managed Health Care	11.14
Life Sciences Tools & Services	8.96
Health Care Supplies	3.21
Health Care Technology	3.06
Health Care Services	2.52
Health Care Facilities	1.35
Drug Retail	0.46

Investment results

Average annual total returns (%) as of Sept. 30, 2020

Period	Class A Shares		Class C Shares		Investor Class Shares	Class Y Shares	Style-Specific Index	MSCI World Health Care Index
	Inception: 08/07/89	Max Load 5.50%	Inception: 03/01/99	Max CDSC 1.00%	Inception: 07/15/05	Inception: 10/03/08		
Inception	10.56	10.76	8.72	8.72	8.92	11.24	-	-
10 Years	11.80	12.43	11.59	11.59	12.43	12.71	13.08	13.08
5 Years	6.84	8.05	7.24	7.24	8.05	8.32	9.90	9.90
3 Years	7.56	9.60	8.77	8.77	9.60	9.87	10.63	10.63
1 Year	16.15	22.92	21.01	22.01	22.95	23.23	20.81	20.81
Quarter	-0.26	5.56	4.34	5.34	5.56	5.61	4.78	4.78

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit invesco.com/performance for the most recent month-end performance.

Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary, and you may have a gain or a loss when you sell shares. No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C shares following one year from the date shares were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. The Investor Class shares have no sales charge; therefore, performance is at NAV. Class Y shares have no sales charge; therefore, performance is at NAV. Returns less than one year are cumulative; all others are annualized. Fund performance reflects any applicable fee waivers and/or expense reimbursements. Had the adviser not waived fees and/or reimbursed expenses currently or in the past, returns would have been lower. See current prospectus for more information. Index returns do not reflect any fees, expenses, or sales charges.

Index source: FactSet Research Systems Inc.

Expense ratios	% net	% total	Asset mix (%)	
Class A Shares	1.08	1.08	Dom Common Stock	75.43
Class C Shares	1.83	1.83	Intl Common Stock	22.46
Investor Class Shares	1.08	1.08	Cash	2.67
Class Y Shares	0.83	0.83	Other	-0.56

Per the current prospectus

A negative in Cash or Other, as of the date shown, is normally due to fund activity that has accrued or is pending settlement.

For more information you can visit us at www.invesco.com/us

■ On April 30, 2018, Invesco Global Health Care Fund was renamed Invesco Health Care Fund. Please see prospectus for more information.

Class Y shares and Investor Class shares are available only to certain investors. See the prospectus for more information.

The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

The MSCI World Health Care Index is an unmanaged index considered representative of health care stocks of developed countries. An investment cannot be made directly in an index.

The S&P 500® Index is an unmanaged index considered representative of the US stock market. An investment cannot be made directly in an index.

About risk

Convertible securities may be affected by market interest rates, the risk of issuer default, the value of the underlying stock or the issuer's right to buy back the convertible securities.

Derivatives may be more volatile and less liquid than traditional investments and are subject to market, interest rate, credit, leverage, counterparty and management risks. An investment in a derivative could lose more than the cash amount invested.

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

The health care industry is subject to risks relating to government regulation, obsolescence caused by scientific advances and technological innovations.

The fund is subject to certain other risks. Please see the current prospectus for more information regarding the risks associated with an investment in the fund.

Before investing, investors should carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund(s), investors should ask their advisors for a prospectus/summary prospectus or visit invesco.com/fundprospectus.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Note: Not all products available at all firms. Financial professionals, please contact your home office.

The opinions expressed are those of the fund's portfolio management, are based on current market conditions and are subject to change without notice. These opinions may differ from those of other Invesco investment professionals. Holdings are subject to change and are not buy/sell recommendations.

All data provided by Invesco unless otherwise noted.